# Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

> **NCT01257204** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 196 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** Placebo
- **DRUG:** Daclatasvir
- **DRUG:** Pegylated interferon alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01257204
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-05
- **Final completion:** 2012-09
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2015-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01257204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01257204, "Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01257204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*